On 21 October, the biotechnology company Biogen reported its third quarter 2020 financial results. In the third quarter, Biogen continued to execute on its strategy and had a total revenue of USD 3,376 million. In this press release, it was also disclosed that Biogen submitted the Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the review of aducanumab as a treatment for Alzheimer’s disease (AD). The application is subject to validation of whether the EMA accepts the application for review.
https://investors.biogen.com/static-files/9d0b52a8-22b5-4742-af9d-8138469ac89f
